Odomzo Approved for Recurring Basal Cell Carcinoma

July 24, 2015 5:35 PM

7 0

FRIDAY, July 24, 2015 (HealthDay News) -- Odomzo (sonidegib) has been approved by the U.S. Food and Drug Administration to treat basal cell carcinoma skin cancer that has returned despite surgery or radiation.

The treatment is sanctioned for people who are not candidates for additional surgery or radiation.

Also read: More than 100 pounds of drugs expected during take back day

Read more

To category page